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gery and axillary surgery, radio-oncology and sys-
temic therapy options in consideration of tumor biol-
ogy, and the clinical application of multigene assays. 
This year, the consensus conference took place in Vi-
enna. From a German perspective, it makes sense to 
substantiate the results of the vote of the international 
panel representing 19 countries in light of the updated 
national therapy recommendations of the AGO (Ar-
beitsgemeinschaft Gynäkologische Onkologie). There-
fore, 14 German breast cancer experts, 3 of whom are 
members of the International St. Gallen Panel, have 
commented on the voting results of the St. Gallen 
Consensus Conference 2015 in relation to clinical rou-
tine in Germany. 
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Summary
The key topics of this year’s 14th St. Gallen Consensus 
Conference on the diagnosis and therapy of primary 
breast cancer were again questions about breast sur-
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Introduction
The panel of this year’s 14th St. Gallen International Breast 
Cancer Conference comprised 49 experts from 19 countries, 3 of 
whom were from Germany. Recommendations are based on the 
majority vote of the panelists who represented various disciplines 
and countries with different healthcare systems and resources. 
Therefore, these are rather personal opinions which are in part 
based on evidence [1]. In light of these facts, however, it makes 
sense to discuss the voting results critically with regard to the na-
tional therapy recommendations of the AGO (Arbeitsgemeinschaft 
Gynäkologische Onkologie) guideline commission from 2015 [2]. 
Rationale and Voting Rules of the St. Gallen Consensus
The St. Gallen Consensus aims essentially at panel members 
forming a majority and giving a practical opinion. Some questions 
were answered with ‘yes’ (consent), ‘no’ (rejection), or ‘abstention’ 
(insufficient data; inability to form an opinion) while others re-
quired choosing from several options. 
Surgical Therapy
Resection Margin after Breast-Conserving Surgery
With regard to breast-conserving therapy, the panelists demand 
unanimously resection with tumor-free resection margins (R0) (no 
invasive tumor cells on ink).
Vote of the German group of experts: Consent. 
According to the majority vote in St. Gallen, breast-conserving 
surgery (BCS) can be performed both in multifocal (yes: 71%) as 
well as multicentric (unilateral; yes: 80%) invasive breast cancer, 
provided the resection margin is tumor-free and patients receive 
adjuvant radiation therapy.
Comment of the German group of experts: Limited consent. Ac-
cording to the 2015 AGO recommendation, BCS must be based on an 
individual decision in multicentric (unilateral) breast cancer [2]. An-
other option is modified mastectomy with immediate reconstruction. 
The size of the resection margin should not depend on tumor 
biology. An additional (larger) margin is not necessary in younger 
patients (< 40 years) and patients with lobular breast cancer. The 
same applies to surgery following neoadjuvant chemotherapy 
(NACT) or if there is an extensive intraductal component.
Vote of the German group of experts: Consent. However, for 
ductal carcinoma in situ, the German group recommends a resec-
tion margin of at least 2 mm after BCS [2].
Surgical Approach Following NACT
The question of whether it is sufficient to perform a sentinel 
node biopsy (SNB) or whether a complete axillary lymph node dis-
section (ALND) should be performed in a patient who has palpa-
tory and/or sonographically suspicious lymph nodes (cN+) at pres-
entation but clinically/sonographically uninvolved axillary nodes 
(ycN0) following NACT (so-called ‘down-staging’), was exten-
sively discussed. The majority of the St. Gallen panelists believe 
that SNB is an adequate approach in patients following NACT. 
However, the St. Gallen panel believes that ALND should be per-
formed if 1 or more sentinel lymph nodes are infiltrated.
Vote of the German group of experts: Consent. This recommen-
dation is based on data of the ACOSOG study Z1071 [3]. The Ger-
man group adds that fine needle aspiration (FNA) or punch biopsy 
prior to NACT should be performed in clinically suspicious lymph 
nodes. If possible, the lymph node in question should be marked 
with a clip. In the case of ycN0, the German group recommends 
deciding on an individual basis whether SNB or ALND should be 
performed [2]. If patients with cN+ (proven by FNA or biopsy) 
prior to NACT undergo an SNB procedure after NACT, the deci-
sion for ALND depends on the number of removed (sentinel and 
non-sentinel) lymph nodes. 
Moreover, the German group points out that only with 3 tu-
mor-free lymph nodes the false-negative rate (FNR: negative senti-
nel node but positive axillary) is similar to the FNR with a primary 
surgical approach. In these cases, the possibility to avoid ALND 
should be discussed with the patient. However, ALND should be 
performed in a patient with histologically positive lymph node(s) 
(by FNA or biopsy) prior to NACT and 1–2 positive sentinel (and 
non-sentinel) lymph nodes following NACT (ypN+ SN) [3–5] 
(fig.  1). Breast surgery following NACT should be performed 
within the new margins.
According to the St. Gallen vote, ALND is not required if 1–2 
macrometastatically infiltrated sentinel lymph nodes are detected 
at primary surgery, provided that ACOSOG Z0011 criteria [6] are 
fulfilled (tumor  5 cm (pT1–2), no extracapsular lymph node in-
volvement, BCS, adequate adjuvant systemic therapy, adjuvant 
postoperative tangential field radiation). 
Vote of the German group of experts: Consent. After mastec-
tomy, ALND should be performed in the case of macrometastati-
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Fig. 1. Surgical procedure of the axilla before or after NACT. 
SLNB = Sentinel lymph node biopsy; NACT = neoadjuvant chemotherapy; LoE = 
level of evidence; GR = grade of recommendation; BET = breast-conserving ther-
apy; ALND = axillary lymphadenectomy; CNB = core needle biopsy; FNA = fine 
needle aspiration; ACOSOG = American College of Surgeons Oncology Group.
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cally involved sentinel lymph nodes [2]. If patients receive postop-
erative adjuvant radiotherapy to the chest wall, the alternative to 
ALND is radiotherapy in the axillary field.
Adjuvant Radiation Therapy
Partial Breast Radiation after BCS
The majority of the St. Gallen panelists believe that partial irra-
diation without whole breast radiation is possible for patients who 
are classified as ‘suitable’ according to the ASTRO (American Soci-
ety for Radiation Oncology) and ESTRO (European Society for Ra-
diotherapy and Oncology) criteria [7, 8]. 
Comment of the German expert group: ASTRO classifies patients 
as ‘suitable’ if they meet the following criteria:   60 years, no 
BRCA1/2 mutation, hormone receptor (HR)-positive, tumor 
 2 cm (T1), clear margin  2 mm, pN0, no lymph vessel infiltra-
tion (L0), unicentric/unifocal, invasive ductal or other favorable 
histology (mucinous, tubular, colloid), missing extensive intra-
ductal component. In patients with DCIS or preceding neoadju-
vant chemotherapy, partial breast irradiation is not indicated. 
However, first positive data have been published on intraoperative 
radiotherapy (IORT) following NACT. The selection criteria (‘suit-
able’) of ESTRO and ASTRO differ only slightly with regard to age 
(  50 vs.  60 years) and T-stage (pT1–2 vs. T1). Other than that, 
the ASTRO criteria fully apply [7–10]. 
The St. Gallen panel recommends for patients classified as ‘in-
termediate’ by ESTRO and as ‘cautionary’ by ASTRO [7, 8] to 
await the results from studies with partial breast irradiation. 
Comment of the German expert group: The patient selection cri-
teria are not sufficiently defined. In this context, it is recommended 
to conduct further clinical trials. In addition, the German expert 
group refers to the current AGO recommendations 2015 [2]. Cur-
rently, there is no general standard for partial breast radiation ther-
apy alone. Partial breast irradiation should be discussed on an indi-
vidual basis with patients who have favorable tumor biology and a 
low risk of recurrence (see [2]). 
Hypofractionated Radiation Following BCS
The St. Gallen panelists believe that hypofractionated radiation 
is indicated regardless of age. In addition, according to the St. 
Gallen vote, it is also indicated for patients with prior chemother-
apy or axillary lymph node involvement regardless of age; there-
fore, irradiation of the lymphatic drainage areas would also be 
indicated. 
Vote of the German group of experts: No consent. The German 
experts recommend a significantly more differentiated approach as 
specified in the current AGO recommendations (fig.  2) [2]. The 
German experts believe that hypofractionated radiation (without 
boost; 15–16 fractions with 2.67 Gy each) following BCS is prefer-
able for patients > 65 years with low risk factors (see ASTRO and 
ESTRO criteria) over normofractionation (25 fractions of 2  Gy 
each). In 40–65-year-old patients with higher risk factors, both 
conventional radiation with integrated or sequential boost and hy-
pofractionated radiation with sequential boost are valid treatment 
options. The AGO does not believe that hypofractionated radiation 
is indicated in women younger than 40 years nor if irradiation of 
the supra-infraclavicular lymphatic drainage areas is indicated; in 
these cases, conventional radiation is recommended. 
Radiotherapy to the Lymphatic Drainage Areas Following BCS
Patients without lymph node involvement (pN0) do not require 
adjuvant radiation therapy of the lymphatic drainage areas follow-
ing BCS. Sole radiation therapy to the breast is insufficient in pa-
tients with lymph node involvement. These patients receive radia-
tion therapy to the regional lymph nodes, however, not including 
the internal mammary lymph nodes. 
Vote of the German group of experts: Consent. In addition, the 
German group of experts refers to the current AGO guideline 2015 
[2], differentiating between 1–3 and   4 involved lymph nodes. 
According to AGO, if 4 or more lymph nodes are involved, there is 
an indication for additional radiotherapy to the lymphatic drainage 
areas. If 1–3 lymph nodes are involved, DEGRO (German Society 
for Radiation Oncology) and AGO differ in their interpretation of 
the data. DEGRO considers this intervention as indicated if 1–3 
lymph nodes are involved while according to AGO it is indicated 
only if additional risk factors such as young age and unfavorable 
tumor biology are present.
Radiotherapy Following Mastectomy
In this case, a differentiation must be made between the indica-
tion for radiation therapy to the thoracic wall and radiation ther-
apy to the lymphatic drainage areas. Radiation therapy to the lym-
phatic drainage areas follows the same rules as that after BCS. AGO 
recommends [2] for patients after mastectomy adjuvant radiation 
therapy to the thoracic wall as standard in T3/T4 carcinomas (ex-
cept ‘low risk’), in involved lymph nodes (DEGRO recommends it 
at ‘any risk’, AGO differentiates here between ‘high’ and ‘low risk’), 
as well as for patients in whom R0 resection could not be achieved. 
Fig. 2. Radiotherapy (RT) after breast-conserving surgery (invasive cancer): 
whole breast irradiation (LoE: Level of evidence).
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The majority of the St. Gallen panelists confirm that patients 
should receive adjuvant radiation therapy after mastectomy and 
with a tumor size of more than 5 cm. They do not believe that adju-
vant radiation therapy is generally indicated in patients with 1–3 
involved lymph nodes; however, they recommend it if the tumor 
biology is unfavorable. Moreover, half of the panelists believe that 
adjuvant radiation therapy is indicated in young women (<  40 
years) with 1–3 involved lymph nodes.
Vote of the German group of experts: Consent. In accordance 
with the AGO recommendation 2015 [2], the indication should be 
risk-adapted, specifically in patients with 1–3 involved axillary 
lymph nodes. According to AGO, a low local risk of recurrence can 
be assumed if at least the following 4 factors are present: pT1, grade 
1, HR-positive, HER2-negative. At a younger age (< 45 years), an 
increased local risk of recurrence is assumed if the tumor location 
is medial or the HR status is negative [2].
The St. Gallen panelists believe that adjuvant radiation therapy 
is indicated after mastectomy and in patients with positive SNB if 
an ALND was not performed. The panelists believe it is not indi-
cated if the lymph nodes were tumor-free (pN0) following ALND, 
if no SNB was performed, and if less than 8 lymph nodes were re-
moved and histologically examined.
Comment of the German group of experts: The German group 
refers again to the AGO recommendations 2015 [2], recommending 
an indication for adjuvant radiation therapy after mastectomy in 
pT3 pN0 patients dependent on the risk constellation: Without ad-
ditional risk factors, adjuvant radiation therapy is a ‘can’ option; in 
young women with increased risk (e.g. an unfavorable tumor biol-
ogy), adjuvant radiation is strongly recommended (LoE 1a A ++). 
If adjuvant radiotherapy is indicated after mastectomy, the ma-
jority of the St. Gallen panelists voted for applying radiation ther-
apy to the regional lymph nodes – without including the internal 
mammary lymph nodes – in addition to the thoracic wall. How-
ever, one third of the panelists abstained from voting.
Comment of the German group of experts: According to the 
AGO recommendation – in accordance with the data of the 
EORTC study by Poortmans et al. [11] – adjuvant radiation ther-
apy to the internal mammary lymphatic drainage region can be 
considered in stage pN1–2 with positive HR expression if adjuvant 
chemotherapy was administered due to an overall high risk (LoE 
2b ++). In pN0 patients with centrally or medially located breast 
cancer and increased risk, there is no strong recommendation for 
thoracic wall radiotherapy; this should be individually discussed 
with the patient (AGO recommendation 2015: LoE 1b B +/-). Ad-
juvant radiation therapy to the internal mammary lymph node re-
gion should not be performed in the case of cardiac risk or trastu-
zumab therapy [2].
In the case of breast reconstruction, the St. Gallen panel recom-
mends radiation of the thoracic wall and the regional lymphatic 
drainage area without the internal mammary lymph nodes.
Comment of the German group of experts: The indication for ad-
juvant radiation therapy should be clarified prior to reconstruction 
(increased rate of capsular fibrosis, worse cosmetic results, higher 
complication rate in late reconstructions). This must be carefully 
considered and discussed with the patient, particularly in the case 
of node-negative breast cancer or 1–3 involved lymph nodes. 
After NACT, the indication for adjuvant radiation therapy is 
based on the initial tumor stage (before NACT), especially in con-
sideration of lymph node involvement histologically verified by 
FNA or biopsy or a positive sentinel lymph node.
Vote of the German group of experts: Consent.
Focus on Pathology
In general, the subtypes luminal A or luminal B (HER2-negative) 
can be differentiated from one another by the estrogen receptor (ER) 
and progesterone receptor (PR) status and the proliferation marker 
Ki-67. If Ki-67 is considered as a decision-making criterion, then 
one part of the St. Gallen panelists (36.4%) require a Ki-67 level of at 
least 20–29% as cut-off for a luminal B carcinoma. Uncertainty with 
regard to the subtype assignment and the therapeutic consequences 
is still present in intermediate Ki-67 levels of 10–13%.
Comment of the German group of experts: In luminal A breast 
cancers, the Ki-67 level is likely to be  10%, even if it is not possi-
ble to define a clear cut-off level.
According to the St. Gallen vote, risk stratification with multi-
gene expression tests cannot replace immunohistological determina-
tion of the intrinsic subtype but can supplement it in doubtful cases. 
For differentiation between luminal A and luminal B type (HER2-
negative) breast cancer, a multigene expression test is only helpful in 
unclear cases, e.g. with an intermediary Ki-67 level of 10–35%.
Vote of the German group of experts: Consent.
In triple-negative breast cancer (TNBC) or HER2-positive 
breast cancer, the role of tumor-infiltrating lymphocytes was dis-
cussed. According to the majority votes of the St. Gallen panelists, 
the extent of lymphocyte infiltration is currently neither a prognos-
tic nor a predictive marker. 
Vote of the German group of experts: Consent. It is anticipated 
that new research results show that lymphocytes will have predic-
tive and potentially therapy-relevant significance in the future [12].
Significance of Multigene Expression Signatures
The St. Gallen panel voted individually on the prognostic and 
predictive value of each of the multigene assays currently available: 
Oncotype DX® Recurrence Score (RS) (Genomic Health, Inc., Red-
wood City, CA, USA), MammaPrint 70® (MP) (Agendia Inc., Ir-
vine, CA, USA), Prosigna® PAM50 Risk of Recurrence Score (ROR) 
(nanoString, Seattle, WA, USA), EndoPredict® (EP) (Myriad Genet-
ics, Salt Lake City, UT, USA), and Breast Cancer IndexSM (BCI). 
With a clear majority of 58.3–92.9%, the St. Gallen panelists see 
in the multigene assays (RS, ROR, EP) a possibility of gaining prog-
nostically relevant information in patients with ER-positive and 
HER2-negative early breast cancer. However, most panelists do not 
believe that these assays provide any prognostically relevant infor-
mation beyond 5 years. Here, the majority vote (63.2%) was only 
positive for the ROR score whereas 40% of the panelists voted for 
the EP score.
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Comment of the German group of experts: The German experts 
point out that the EP and the ROR provide equally valid data to as-
sess the risk of recurrence in HR-positive postmenopausal patients 
even beyond the 5th year following the initial diagnosis.
Reliable predictive significance regarding additional adjuvant chem-
otherapy is confirmed only for the Oncotype DX by the majority 
(80.5%) of the St. Gallen panelists. So far, there are no prospective study 
data for any of the multigene assays which would prove their predictive 
significance; there are only retrospective data for Oncotype DX [2]. In 
general, the panelists recommend a multigene assay in addition to the 
Ki-67 in node-negative carcinomas (HR-positive, HER2-negative) if 
there is no consensus as to whether chemotherapy is indicated.
Comment of the German group of experts: Multigene tests are 
only justified if the indication for chemotherapy is not clear based 
on the histopathological findings. The statement of the German 
working group on the clinical benefit of the above-referenced multi-
gene assays is summarized in table 1. The evidence situation assessed 
by the AGO differs in part from that of the St. Gallen panel [2].
Endocrine Treatment
Additional Ovarian Function Suppression for Premenopausal 
Patients?
In light of the SOFT study [13], the St. Gallen panelists believe 
additional ovarian function suppression (OFS; with gonadotropin-
releasing hormone (GnRH), bilateral oophorectomy, or bilateral 
radiation of the ovaries) is an option for young (  35 years) pre-
menopausal patients if they present with premenopausal estrogen 
serum levels after (neo)adjuvant chemotherapy.
Vote of the German group of experts: Consent. The German ex-
perts point out that aromatase inhibitors (AI) or tamoxifen com-
bined with OFS have significantly more side effects than tamoxifen 
alone. This requires informing the patient diligently.
In addition, the St. Gallen panelists do believe OFS is indicated 
if: i) 4 or more lymph nodes are involved (89.7%); ii) in G3 breast 
cancer (55.9%); and iii) if a multigene test points toward an in-
creased risk (60%). 
Vote of the German group of experts: No consent. Grading, lymph 
node involvement, and the results of a multigene test are not suffi-
cient as sole factors to justify additional OFS. There are no prospec-
tive data to support this recommendation. In this situation, the Ger-
man working group primarily sees an indication for chemotherapy.
Tamoxifen or AIs plus OFS for Premenopausal Patients?
The majority of the St. Gallen panelists voted for a combination 
with an AI in younger women (   35 years: 59.4%) if 4 or more 
lymph nodes are involved (92.5%), if there is an increased risk ac-
cording to multigene tests (65.8%), and – with a narrow majority 
(57.1%) – in the case of a G3 carcinoma. A slight majority (51.2%) 
were against AIs as combination partner in patients who remain 
premenopausal after completed adjuvant chemotherapy.
Vote of the German expert group: No consent. The questions 
selected for voting refer to a retrospective assessment of the SOFT 
study [13]. The SOFT study does not provide data on overall sur-
vival. Although the patient cohorts are comparable to only a lim-
ited extent, the data of the SOFT/TEXT study contradict the Aus-
trian ABCSG12 study [14]. After a median follow-up of 9.4 years, 
there was no difference in disease-free survival (DFS) between ta-
moxifen alone versus anastrozole alone, but there was a decidedly 
higher risk of death for patients treated with anastrozole and OFS 
compared to tamoxifen/OFS (hazard ratio 1.63; 95% confidence 
interval 1.05–1.45; p = 0.030). 
The St. Gallen panelists voted with 56.7% for OFS over 5 years.
Comment of the German group of experts: The German experts 
recommend primarily 2–3 years, and – depending on side effects 
and risks – a maximum OFS period of 5 years. Before menopause, 
an AI must always be combined with OFS.
The Postmenopausal Patient
Treatment with tamoxifen remains an adequate option for post-
menopausal patients with early hormone-sensitive breast cancer. 
However, preference should be given to an AI if the risk is in-
creased. If an AI is indicated, it should be given ‘upfront’ if the risk 
is increased. In the case it is not well tolerated, the ‘switch’ to ta-
moxifen is an option after 2 years. 







PAM50 ROR (Prosigna) 92%a 63%a 38%c
Recurrence Score (Oncotype Dx) 83%a 44%c 80%a,b
Endopredict 70%a 38%c 38%
MammaPrint 81%a 33%c 30%c
Consent with the following limitations:
aShould only be used in selected patients if all other criteria do not permit any clinical decision-making 
 option.
bValidated clinical data are available for this assay only.
cThe contemplated option differs in part from the evidence situation (see AGO).
PAM50 = Prediction analysis of Microarrays 50; ROR = risk of recurrence.
Table 1. Gene expression tests in luminal breast 
cancer: St. Gallen Consensus 2015
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Vote of the German group of experts: Consent. However, the 
German experts recommend AIs to be used for lobular carcinoma. 
They refer to the ATAC and BIG 1–98 data [15, 16].
Therapy Duration up to 10 Years?
Extended adjuvant aromatase inhibitor therapy (EAT) over the 
course of 10 years after surgery is an important option in patients 
at increased risk regardless of menopausal status. Before meno-
pause, EAT can be done with tamoxifen, during the postmenopau-
sal period with tamoxifen or an AI.
Vote of the German group of experts: Consent. 
Extended Endocrine Therapy after the ‘Switch’ Therapy 
If EAT is indicated in patients who received 2 years of treatment 
with tamoxifen followed by 3 years of treatment with an AI, these 
patients should either be treated for an additional 5 years with ta-
moxifen or for an additional 2 years with an AI according to the St. 
Gallen vote.
Vote of the German group of experts: Consent. The German 
group of experts consider that continued use of both an AI for 2 
years or tamoxifen for 5 years might be clinically reasonable even if 
no clear data on a face-to-face comparison of this option are avail-
able to support this issue. In contrast, at present there are no data 
available to support the use of an AI beyond 5 years, as recom-
mended by Burstein et al. [17]. There may be clinical scenarios 
where such a decision might be useful, but only on an individual 
informed consent basis.
Extended Endocrine Treatment Following Upfront AI Therapy 
For this situation also there are currently no data from clinical 
trials. With a slight majority, the panelists rejected continued treat-
ment with both tamoxifen and an AI. With 54.5%, a narrow major-
ity voted for not continuing any further endocrine therapy in these 
patients.
Vote of the German group of experts: Consent. The experts 
agree that in the case of unacceptable toxicity caused by an AI, ta-
moxifen can be used again. Tamoxifen exposure should be limited 
to 5 years in this setting. If treatment-related toxicities might influ-
ence compliance or adherence, a change to another endocrine 
treatment option is highly recommended to avoid treatment dis-
continuation in the adjuvant setting.
Focus on Adjuvant Chemotherapy
Luminal A Breast Cancers
Luminal A breast cancer is defined by high HR expression, 
HER2 negativity, and a low proliferation rate. Therefore, the ther-
apy of choice is endocrine intervention. Additional adjuvant chem-
otherapy is generally not indicated and should only be considered 
on an individual basis if the risk is increased (e.g.   4 involved 
lymph nodes, T3). If only 1–3 lymph nodes are involved and there 
are no additional risks, additional adjuvant chemotherapy is not 
indicated.
Vote of the German group of experts: Consent.
The majority (67.6%) of the St. Gallen panelists regard lympho-
vascular tumor invasion as a sole indication for adjuvant 
chemotherapy.
Vote of the German group of experts: No consent.
Luminal B Breast Cancer without Overexpression of HER2
Endocrine treatment is an important component of systemic 
therapy also for patients with luminal B carcinoma. If the risk of 
recurrence is increased, adjuvant chemotherapy is indicated. If 
chemotherapy is indicated, an anthracycline/taxane-containing 
regimen is preferable. 
Vote of the German group of experts: Consent. For example, the 
German experts recommend 4 cycles of anthracycline/cyclophos-
phamide followed by 12 weeks of paclitaxel administered weekly, 
or 6 cycles of docetaxel/doxorubicin/cyclophosphamide (TAC) ad-
ministered every 3 weeks. If the risk of recurrence is high (e.g.  4 
involved lymph nodes), a dose-dense regimen with granulocyte-
colony stimulating factor (G-CSF) support is one therapy option.
In the case of low risk scores in the available multigene expres-
sion tests (RS, MP, PAM50 ROR, EP), there is no indication for 
adjuvant chemotherapy in patients with up to 3 involved lymph 
nodes.
Vote of the German group of experts: Consent. The first pro-
spective data of the PlanB study (HR-positive, HER2-negative) 
show that patients with 0–3 involved lymph nodes and a low risk 
score (   11) have an excellent 3-year survival rate of over 98% 
[18]. In this context, the results of the ongoing clinical trials 
 (TailorX, RxPONDER, MINDACT, PlanB, ADAPT) need to be 
awaited.
TNBC
For patients with TNBC (ER, PR, HER2), anthracycline/taxane-
containing regimens are the therapy of choice. The same applies to 
patients with a BRCA mutation. Dose-dense regimens (with G-CSF 
support) can be an option according to the panelists (yes 45%, no 
52.5%). The majority (92.9%) of panelists do not see a general indi-
cation for platinum-containing regiments in early TNBC.
Vote of the German group of experts: Consent.
A slight majority (57.9%) of the St. Gallen panelists consider 
platinum in patients with TNBC and a BRCA mutation as an ad-
ditional option.
Comment of the German group of experts: The German experts 
recommend a more differentiated approach. Because of the lack of 
prospective data, they do not agree to the use of platinum in the 
adjuvant situation. These patients should receive neoadjuvant 
treatment, and, if possible, they should be included in clinical 
trials.
HER2-Positive Early Breast Cancer
If HER2 positivity is proven according to the requirements of 
the ASCO/CAP guidelines [19], an adjuvant anti-HER2 targeted 
therapy is indicated even at tumor stage T1b, according to the ma-
jority vote of the St. Gallen panelists (81.4%). From stage T1c and 
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higher, all St. Gallen panelists voted for adjuvant chemotherapy in 
combination with an anti-HER2 targeted therapy.
Vote of the German group of experts: Consent. Adjuvant chemo-
therapy should preferably consist of a sequential anthracycline/
taxane-containing regimen. The anti-HER2 targeted therapy is ap-
plied in parallel to the taxane. Standard is a 1-year therapy with 
trastuzumab. In patients with node-negative T1b/c carcinoma, it 
may make sense to combine 12× paclitaxel (weekly) with trastu-
zumab (1 year; without anthracyclines) [20].
Focus on Neoadjuvant Therapy
HER2-Positive Breast Cancer 
The standard for neoadjuvant therapy of HER2-positive breast 
cancer is sequential anthracycline/taxane-based chemotherapy plus 
trastuzumab. In addition, the majority (73%) of the St. Gallen pan-
elists also see a neoadjuvant indication for dual horizontal block-
ade with pertuzumab in combination with trastuzumab and a 
taxane.
Vote of the German group of experts: No consent with regard to 
the dual horizontal blockade. In Europe, pertuzumab/trastuzumab/
taxane – in contrast to the United States – is currently not ap-
proved for neoadjuvant treatment of HER2-positive breast cancer. 
Without approval, the dual blockade with pertuzumab and trastu-
zumab in the neoadjuvant situations can presently only be decided 
upon on an individual basis in Germany. The German experts add 
that for patients with cardiac risks, the anthracycline-free TCH 
regimen (docetaxel, carboplatin, trastuzumab) is an additional ne-
oadjuvant therapy option.
TNBC
Sequential regimens with an anthracycline combination fol-
lowed by a taxane are indicated in TNBC. The inverse sequence 
achieves at least comparable response rates. 
Vote of the German group of experts: Consent. The results of the 
GeparSepto study demonstrated a significantly higher pathologic 
complete remission (pCR) rate with weekly nab-paclitaxel com-
pared to weekly paclitaxel – each followed by 4 cycles of epirubicin/
cyclophosphamide (EC) administered every 3 weeks. The benefit 
was shown for all patients and was particularly pronounced in 
TBNC (doubling of the pCR rate) [21]. Further study results 
(ETNA, ADAPT) are expected. 
The St. Gallen panel does not recommend platinum for neoad-
juvant treatment of TNBC.
Vote of the German group of experts: No consent. Data from 
several prospective, randomized, neoadjuvant studies [22–24] 
demonstrate a clear advantage of platinum, particularly in patients 
with a family history or BRCA mutations (table 2). For this reason, 
the AGO has assigned a ‘+’ recommendation for neoadjuvant plati-
num [1]. 
Luminal A Breast Cancer
The majority of the St. Gallen panelists believe that neoadjuvant 
chemotherapy is an option for patients who cannot undergo BCS. 
Vote of the German group of experts: No consent. Currently, 
neoadjuvant chemotherapy is not an option in luminal A breast 
cancers. The German experts emphasize that neoadjuvant chemo-
therapy is rarely indicated in patients with luminal A breast cancer. 
Based on the low sensitivity to chemotherapy, it seems unlikely 
that the tumor would decrease in size (pCR) and outcome subse-
quently improve. 
Neoadjuvant Endocrine Therapy 
Neoadjuvant endocrine therapy can be a meaningful option for 
postmenopausal patients with an endocrine sensitive breast 
cancer.
Vote of the German group of experts: Limited consent. Based on 
the limited available data, neoadjuvant endocrine therapy should 
only be considered for older patients with clinically relevant inter-
nal comorbidities. 
Optimum therapy duration is not known. The majority of the 
St. Gallen panelists recommend administering a neoadjuvant en-
docrine therapy for either several (4–8) months or up to the maxi-
mum response. 
Comment of the German expert group: The German experts 
point out that these patients should undergo surgery if at all 
possible.
Author [ref.] Study Regimen pCR rate




paclitaxel 80mg/m² qw ×12 + Cb 
AUC 6 q3w ×4 – dd AC q2w ×4
TNBC ± Cb: 54 vs. 41% 
(ypT0/is ypN0)




NPLD 20 mg/m² qw ×18 + paclitaxel 
80 mg/m² qw ×18 + Cb AUC 1.5 qw 
×18 + Bev 15 mg/kg q3w ×6
TNBC ± Cb: 53 vs. 37%
(ypT0 ypN0)
Ando M et al. [24] phase II paclitaxel 80 mg/m² qw ×12 + Cb 
AUC 5 q3w ×4 – FEC q3w ×4 
TNBC ± Cb: 61 vs. 26%
pCR = Pathologic complete remission; AUC = area under the curve; dd = dose-dense; AC = adriamycin,  
cyclophosphamide; NPLD = non-pegylated doxorubicin; TNBC = triple-negative breast cancer; Cb = carboplatin;  
Bev = bevacizumab; qw = weekly; q2w = every 2 weeks; q3w = every 3 weeks; FEC = 5-fluorouracil, epirubicin,  
cyclophosphamide; CALGB = Cancer and Leukemia Group B.
Table 2. Superiority 
of carboplatin-contain-
ing regimens in the 
 neoadjuvant setting [1]
Jackisch  et al.Breast Care 2015;10:211–219218
Adjuvant Use of ‘Bone-Modifying Agents’  
(Bisphosphonates, Denosumab)
The Postmenopausal Patient
The adjuvant use of a bisphosphonate (BP; zoledronic acid 
every 6 months, or orally with clodronic acid daily) in addition to 
adjuvant endocrine therapy can be an option for postmenopausal 
patients with the goal to prolong DFS.
Vote of the German group of experts: Consent. The data of a large 
meta-analysis show that an adjuvant effect of BP is limited to post-
menopausal patients [25]. It should be pointed out that BP are only 
approved for the treatment of osteoporosis and osseous metastases.
The Premenopausal Patient 
Based on the data of the Austrian ABCSG 12 study [13], adjuvant BP 
administration in premenopausal patients along with GnRH may be an 
option in certain cases; however, it is not the general standard. There are 
no data and therefore no indication for adjuvant use of denosumab.
Vote of the German group of experts: Consent.
Focus on Elderly and Younger Patients
In patients without clinically relevant (significant) comorbidi-
ties, the use of adjuvant standard (chemo)therapy should not gen-
erally be made dependent on age. The same applies to the question 
of whether after BCS a postmenopausal patient with ER-positive 
breast cancer should not have adjuvant radiation if adjuvant endo-
crine therapy is continued. The indication for an adjuvant therapy 
should be based on life expectancy (biological age).
Vote of the German group of experts: Consent.
Testing for Mutations
In younger patients (< 40 years) with TNBC, genetic counsel-
ling along with BRCA1/2 testing should be carried out according to 
the majority vote (73%) of the St. Gallen panel. On the additional 
question of whether this should also apply to the age limit of < 60 
years, the St. Gallen panel voted 50: 50. The majority (90.9%) voted 
in favor of the test for patients with TNBC and a positive family 
history. The St. Gallen panel rejected with a narrow majority (50%) 
further mutation tests in other genes.
Vote of the German group of experts: Consent.
A test for high-risk mutations (such as PALB2) does not gener-
ally make sense for all breast cancer patients; however, it is recom-
mended if the family history is positive and if the patient is  35 
years. There is no general indication for testing patients < 50 years; 
however, testing is indicated in those with ER-negative and HER2-
negative breast cancer (70%).
Vote of the German group of experts: Consent. However, the test 
should only be performed if therapeutically relevant. The  German 
experts recommend patients with ER- and HER2-negative breast 
cancers should be generally tested regardless of the patient’s age, 
provided the result can affect the therapy decision (e.g. prophylac-
tic mastectomy, bilateral prophylactic salpingoophorectomy). 
The probability to find any mutations decreases with increasing 
age.
Vote of the German group of experts: Consent plus supplement: 
This applies also to patients with ‘basal-like’ breast cancer. 
The presence of a BRCA1/2 mutation can only affect the neoad-
juvant therapy; however, it does not affect the adjuvant therapy de-
cision due to lack of data.
Vote of the German group of experts: Consent. 
Fertility Preservation in Young Patients
Young patients should be informed and counseled on the pos-
sibility of fertility preservation if indicated. The use of a GnRH an-
alogue before and during adjuvant chemotherapy may be an op-
tion in individual cases. 
Vote of the German group of experts: Consent. 
The majority (78.9%) of the St. Gallen panelists voted for offer-
ing young patients (<  40 years) with HR-negative breast cancer 
OFS in addition to the chemotherapy.
Vote of the German group of experts: No consent. With reference 
to the current therapy recommendations of AGO Mamma, the Ger-
man experts recommend OFS based on individual criteria [2]. 
Breast Cancer and Pregnancy
If a patient is diagnosed with breast cancer during pregnancy, 
then labor should not be induced prematurely. It is possible to un-
dergo BCS. It is possible to perform lymph scintigraphy and SNB. 
If endocrine therapy is indicated, it should be started post-partum.
Vote of the German group of experts: Consent.
With a low majority (52.6%), the panelists recommend that it 
makes sense to reconstruct the breast immediately in patients who 
undergo mastectomy during pregnancy.
Vote of the German expert group: No consent. Experts refer to a 
longer duration of surgery and an increased risk of complications if 
immediate reconstruction is performed.
If a patient with breast cancer wants to become pregnant, the 
ongoing treatment can be interrupted. The majority (60.6%) of the 
St. Gallen panelists believe that endocrine therapy should only be 
interrupted after 18–30 months provided a pregnancy is desired. 
The majority (61.1%) recommends considering this only if there is 
no notably increased risk of recurrence. 
Vote of the German group of experts: Consent. The German ex-
perts emphasize that the patient should have received tamoxifen 
for at least 18 months because thereafter the annual gain through 
adjuvant therapy decreases in accordance with the EBCTCG 
analysis. 
Diet and Physical Activity
Patients with breast cancer do not require any special diet. 
However, balanced nutrition is generally important for overall 
wellbeing and health. A positive effect on the breast cancer-specific 
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survival rate is not proven. The same applies to regular physical 
activity and moderate exercise, as well as avoiding significant over-
weight. Supplementation is recommended in the case of vitamin D 
deficiency.
Vote of the German group of experts: Consent.
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